Current Pharmaceutical Biotechnology - Volume 19, Issue 8, 2018

Background: RNA is increasingly recognized as a powerful molecule that can be used to control gene expression. Sophisticated, well-engineered RNA-based regulators are being developed as oligotherapeutics. Methods: In particular, small activating RNAs (saRNAs) are promising therapeutic options for targeting human diseases. Numerous saRNAs targeting multiple cancers have been developed in preclinical models. One saRNA targeting C/EBPα is currently undergoing clinical trials in liver cancer. Results and Conclusion: In this review, we describe the current working model of the intracellular mechanism of saRNA, discuss the recent progress of saRNA therapeutics in preclinical and clinical trials, and current advances in targeted delivery using aptamers in detail.

Background: Oligonucleotide drug development has revolutionised the drug discovery field. Within this field, ‘small’ or ‘short’ activating RNAs (saRNA) are a more recently discovered category of short double-stranded RNA with clinical potential. saRNAs promote transcription from target loci, a phenomenon widely observed in mammals known as RNA activation (RNAa). Objective: The ability to target a particular gene is dependent on the sequence of the saRNA. Hence, the potential clinical application of saRNAs is to increase target gene expression in a sequence-specific manner. saRNA-based therapeutics present opportunities for expanding the “druggable genome” with particular areas of interest including transcription factor activation and cases of haploinsufficiency. Results and Conclusion: In this mini-review, we describe the pre-clinical development of the first saRNA drug to enter the clinic. This saRNA, referred to as MTL-CEBPA, induces increased expression of the transcription factor CCAAT/enhancer-binding protein alpha (CEBPα), a tumour suppressor and critical regulator of hepatocyte function. MTL-CEBPA is presently in Phase I clinical trials for hepatocellular carcinoma (HCC). The clinical development of MTL-CEBPA will demonstrate “proof of concept” that saRNAs can provide the basis for drugs which enhance target gene expression and consequently improve treatment outcome in patients.

Background: Small double-strand RNAs (dsRNAs) molecules are able to activate endogenous genes via an RNA-based promoter-targeting mechanism. Like RNA interference (RNAi), RNA activation (RNAa) is an evolutionarily conserved mechanism that is present in diverse eukaryotic organisms ranging from yeast to humans. Methods: The small activating RNAs (saRNAs) that are involved in RNAa have been successively used to activate gene expression in cultured cells. Thus, this emergent technique might allow us to develop biotechnological and therapeutic applications without the need to synthesize hazardous construct systems that harbor exogenous DNA sequences. Result and Conclusion: Accordingly, this article aims to provide insights into how RNAa cellular machinery can be manipulated to activate gene expression and for more effective clinical treatments of diverse diseases.

Background: A novel strategy has been adapted to combat the threat caused by biofilm forming-pathogenic bacteria in our environments. It involves the synthesis of antibiofilm compounds biologically (metabolites from animals, microbes and plants) and chemically. As a result of extensive research, a significant number of antimicrobial compounds and biofilm inhibitors have been isolated and characterized from different biological and chemical sources. However, lots of limitations such as poor delivery, water-insolubility, stability, expulsion by efflux pumps, and the development of acquired resistance due to long-term exposure have been associated with these compounds. Methods: Conjugation or encapsulation of these antibiofilm drugs with different biocompatible, biodegradable, chemically and thermally stable nanomaterials results in enhanced efficiency of biofilm inhibition. Results and Conclusion: This review article evaluates the current impact of antibiofilm drugs including its delivery, efficiency of blocking cell attachment and molecular mechanisms of action that is conjugated or encapsulated with different types of biocompatible nanomaterials. It will lead to a better understanding of the antibiofilm drugs and their role in combating biofilms. It will also open new doors for the application of immobilized antibiofilm drugs.

Apoptosis, a form of programmed cell death, plays a very crucial role in various physiological processes for maintaining cell homeostasis. This process has several characteristic features like membrane blebbing, nuclear condensation, DNA fragmentation and cell shrinkage. Any defect in this highly regulated process eventually leads to extended cell survival and could result in neoplastic cell expansion followed by genetic instability. The apoptotic machinery is mainly processed and regulated by various caspases, a family of cysteine proteases. Significant advancement has been made towards understanding the molecular mechanisms of apoptosis which provides new insights in modulating the life or death of a cell. The main goal of this review is to highlight recent updates on apoptosis, the cross-talk with other cellular death processes and its therapeutic potentials.

Background: An efficient and accurate HPLC method was developed for the determination of menaquinone-7 (MK-7) in microbial fermentation using 2-propanol and n-hexane as extraction solvents as well as the eluent. Methods: Extraction was carried out with 2-propanol and n-hexane (2:1, v/v) after enzymatic hydrolysis with 1% (w/v) lipase and ethanol water treatment prior to quantification in order to remove interfering lipids and denatured proteins. Chromatographic separation of MK-7 was accomplished isocratically on a C 18 Gemini column using a mobile phase mixture of 2- propanol: n-hexane (2:1, v/v) with a flow rate of 0.5 mL/min. UV detection was carried out from 200-400 nm and the chromatogram was extracted at a wavelength of 248 nm. A linear response was shown by the method with a coefficient of determination (R2) value of 0.9982. Results: The recoveries of MK-7 were greater than 94% and the intra and inter day R.S.D values were less than 2%, demonstrating the accuracy of the method. The lower limit of detection (LOD) and the limit of quantification (LOQ) were 0.1 μg/mL and 0.29 μg/mL, respectively. Conclusion: The general usefulness of the described method is demonstrated by the application of this method in the analysis of MK-7 from Bacillus species. Under these conditions, the analysis of MK-7 was achieved in less than 8 minutes with a retention time of 7.19 ± 0.1 minutes.

Background: The impact of antiepileptics on serum vitamin levels is controversial and uncertain. With no clear conclusions on the impact of antiepileptics on serum levels of vitamins, there is a need for further clinical studies in order to ascertain the impact of old and newer antiepileptic drugs on serum levels of vitamins in epileptic patients, thus accomplishing a suitable usage of vitamins supplementation. Objective: The intention of the present research is to confirm the hypothesis of whether or not vitamin levels are altered with antiepileptic drugs. The study also aims to reveal which vitamin levels are particularly more altered, are vitamin levels affected by gender and the type and number of antiepileptics used. Methods: The present research was piloted in collaboration with the Department of Neurology in Qilu Hospital of Shandong University. A total of 63 serum samples of epileptic patients receiving antiepileptics as monotherapy or polytherapy were requested for analysis of nine vitamin serum levels. Total nine vitamins (B1, B2, B6, B9, B12, A, C, D and E) in epileptic patients receiving antiepileptic drugs were analyzed. The serum results of all vitamins were compiled and evaluated with SPSS. Results: It was alarmingly found that serum levels of vitamin D were particularly very low in almost all (90%) epileptic patients in this study. Notably, serum levels of vitamin C and vitamin B1 were also below reference range in 72% and 46% epileptic patients, respectively. The remaining vitamins were almost in reference range for most of the patients. In our study, mean and frequency of vitamin D, C and B1 levels do not vary too much among different gender groups. The patients receiving newer antiepileptic drugs displayed a slightly increased serum vitamin D levels in comparison to the patients receiving older antiepileptic drugs. We found low vitamin D, C and B1 serum levels in patients who were on monotherapy as in comparison with patients on polytherapy. Conclusion: The most significant and surprising finding of this study revealed that serum vitamin D levels in particular were very low in almost all patients and in some patients' vitamin B1 serum levels were also below the reference range. More importantly, it is first time reported here that vitamin C serum levels were also below reference range in the majority of these Chinese epileptic patients. It is recommended that all these vitamins should be regularly monitored in addition to therapeutic drug monitoring of antiepileptic drugs. Additional clinical trials are required for further evaluation. It is also recommended that epileptic patients with low serum levels of these vitamins may be prescribed vitamins supplementations with antiepileptic drugs in order to control their seizures more effectively and efficiently.